Skip to main content
SpringerLink
Log in

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (± 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (≥ 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nolte F, Hofmann WK (2010) Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 6:445–455

    Article  PubMed  CAS  Google Scholar 

  2. Kao JM, McMillan A, Greenberg PL (2008) International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765–770

    Article  PubMed  CAS  Google Scholar 

  3. Neukirchen J, Schoonen WM, Strupp C et al (2011) Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 35:1591–1596

    Article  PubMed  Google Scholar 

  4. Gattermann N, Rachmilewitz EA (2011) Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 90:1–10

    Article  PubMed  CAS  Google Scholar 

  5. Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355:2051–2052

    Article  PubMed  CAS  Google Scholar 

  6. Borgna-Pignatti C, Rugolotto S, De Stefano P et al (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187–1193

    PubMed  Google Scholar 

  7. Takatoku M, Uchiyama T, Okamoto S et al (2007) Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78:487–494

    Article  PubMed  CAS  Google Scholar 

  8. Leitch HA (2007) Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31(Suppl 3):S7–S9

    Article  PubMed  CAS  Google Scholar 

  9. Rose C, Brechignac S, Vassilief D et al (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34:864–870

    Article  PubMed  CAS  Google Scholar 

  10. Steensma DP (2011) The role of iron chelation therapy for patients with myelodysplastic syndromes. J Natl Compr Canc Netw 9:65–75

    PubMed  Google Scholar 

  11. Arboretti R, Tognoni G, Alberti D (2001) Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol 56:915–922

    Article  PubMed  CAS  Google Scholar 

  12. Jensen PD, Jensen IM, Ellegaard J (1992) Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80:121–124

    Article  PubMed  CAS  Google Scholar 

  13. Jensen PD, Heickendorff L, Pedersen B et al (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94:288–299

    Article  PubMed  CAS  Google Scholar 

  14. Guariglia R, Martorelli MC, Villani O et al (2011) Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 35:566–570

    Article  PubMed  Google Scholar 

  15. Gattermann N, Finelli C, Della Porta M et al (2012) Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 97:1364–1371

    Article  PubMed  CAS  Google Scholar 

  16. Breccia M, Finsinger P, Loglisci G et al (2012) Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Ann Hematol 91:1345–1349

    Article  PubMed  CAS  Google Scholar 

  17. List AF, Baer MR, Steensma DP et al (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 30:2134–2139

    Article  PubMed  CAS  Google Scholar 

  18. Hartmann J, Sinzig U, Wulf G et al (2009) Significant suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS and sequential analyses of BFU-E under chelation therapy. ASH Annu Meet Abstr 114:3826

    Google Scholar 

  19. Greenberg PL, Koller CA, Cabantchik ZI et al (2010) Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 34:1560–1565

    Article  PubMed  CAS  Google Scholar 

  20. Cappellini MD, Cohen A, Piga A et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107:3455–3462

    Article  PubMed  CAS  Google Scholar 

  21. Piga A, Galanello R, Forni GL et al (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91:873–880

    PubMed  CAS  Google Scholar 

  22. St Pierre TG, Clark PR, Chua-anusorn W et al (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855–861

    Article  PubMed  CAS  Google Scholar 

  23. Gattermann N, Finelli C, Porta MD et al (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34:1143–1150

    Article  PubMed  CAS  Google Scholar 

  24. List AF, Baer MR, Steensma D et al (2008) Iron chelation with deferasirox (Exjade(R)) improves iron burden in patients with myelodysplastic syndromes (MDS). ASH Annu Meet Abstr 112:634

    Google Scholar 

  25. Lee JW, Yoon SS, Shen ZX et al (2010) Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 116:2448–2454

    Article  PubMed  CAS  Google Scholar 

  26. Bennett JM (2008) Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83:858–861

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    F. Nolte, C. Schumann & W. K. Hofmann

  2. Institut für klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-Württemberg—Hessen und Universität Ulm, Ulm, Germany

    B. Höchsmann & H. Schrezenmeier

  3. Medizinische Klinik II, Hämatologie und Onkologie, St. Johannes Hospital, Duisburg, Germany

    A. Giagounidis

  4. Abteilung für Innere Medizin I, Hämatologie und Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany

    M. Lübbert

  5. Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

    U. Platzbecker

  6. Abteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany

    D. Haase

  7. Onkologisch-urologische Praxis, Rostock, Germany

    A. Lück

  8. Abteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

    N. Gattermann

  9. Institut für Radiologie und Klinik für Strahlenheilkunde, Charité Universitätsmedizin Berlin, Berlin, Germany

    M. Taupitz

  10. Novartis Pharma GmbH, Nürnberg, Germany

    M. Baier, O. Leismann & A. Junkes

Authors
  1. F. Nolte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Höchsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Giagounidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lübbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Platzbecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Haase
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Lück
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Gattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Taupitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Baier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. O. Leismann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. Junkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C. Schumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. W. K. Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H. Schrezenmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Nolte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nolte, F., Höchsmann, B., Giagounidis, A. et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 92, 191–198 (2013). https://doi.org/10.1007/s00277-012-1594-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1594-z

Keywords

Search

Navigation